Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD

4.03  -0.24 (-5.62%)

After market: 4.05 +0.02 (+0.5%)

Fundamental Rating

3

Taking everything into account, MYGN scores 3 out of 10 in our fundamental rating. MYGN was compared to 563 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

MYGN had positive earnings in the past year.
In the past year MYGN has reported a negative cash flow from operations.
In the past 5 years MYGN always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With an excellent Return On Assets value of -11.73%, MYGN belongs to the best of the industry, outperforming 85.61% of the companies in the same industry.
MYGN has a Return On Equity of -17.19%. This is amongst the best in the industry. MYGN outperforms 87.39% of its industry peers.
Industry RankSector Rank
ROA -11.73%
ROE -17.19%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

With an excellent Gross Margin value of 69.89%, MYGN belongs to the best of the industry, outperforming 80.99% of the companies in the same industry.
In the last couple of years the Gross Margin of MYGN has declined.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYGN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MYGN has been increased compared to 5 years ago.
MYGN has a worse debt/assets ratio than last year.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.45, we must say that MYGN is in the distress zone and has some risk of bankruptcy.
MYGN's Altman-Z score of 0.45 is fine compared to the rest of the industry. MYGN outperforms 66.61% of its industry peers.
MYGN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
MYGN's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. MYGN is outperformed by 62.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 0.45
ROIC/WACCN/A
WACC9.83%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

MYGN has a Current Ratio of 1.96. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MYGN (1.96) is worse than 76.02% of its industry peers.
MYGN has a Quick Ratio of 1.78. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MYGN (1.78) is worse than 77.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.78
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

MYGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 237.50%, which is quite impressive.
MYGN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 86.63% yearly.
MYGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.21%.
Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)237.5%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.12%

3.2 Future

The Earnings Per Share is expected to grow by 33.97% on average over the next years. This is a very strong growth
MYGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.25% yearly.
EPS Next Y-39.33%
EPS Next 2Y45.76%
EPS Next 3Y53.71%
EPS Next 5Y33.97%
Revenue Next Year0.79%
Revenue Next 2Y4.51%
Revenue Next 3Y5.51%
Revenue Next 5Y5.25%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

MYGN is valuated quite expensively with a Price/Earnings ratio of 36.64.
Compared to the rest of the industry, the Price/Earnings ratio of MYGN indicates a rather cheap valuation: MYGN is cheaper than 93.61% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.12, MYGN is valued quite expensively.
MYGN is valuated correctly with a Price/Forward Earnings ratio of 14.59.
MYGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 94.32% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.42. MYGN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 36.64
Fwd PE 14.59
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as MYGN's earnings are expected to grow with 53.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.76%
EPS Next 3Y53.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (5/8/2025, 8:11:31 PM)

After market: 4.05 +0.02 (+0.5%)

4.03

-0.24 (-5.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners104.25%
Inst Owner Change-0.74%
Ins Owners2.21%
Ins Owner Change9.41%
Market Cap371.45M
Analysts68.7
Price Target15.33 (280.4%)
Short Float %5.73%
Short Ratio4.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)101.18%
Min EPS beat(2)-2.9%
Max EPS beat(2)205.26%
EPS beat(4)3
Avg EPS beat(4)198.46%
Min EPS beat(4)-2.9%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)133.36%
EPS beat(12)9
Avg EPS beat(12)102.73%
EPS beat(16)13
Avg EPS beat(16)96.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.6%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-0.76%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)2.44%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)0.25%
Revenue beat(16)9
Avg Revenue beat(16)1.25%
PT rev (1m)-12.48%
PT rev (3m)-24.54%
EPS NQ rev (1m)5.84%
EPS NQ rev (3m)-700.41%
EPS NY rev (1m)12.78%
EPS NY rev (3m)-2.11%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)-5.19%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-3.51%
Valuation
Industry RankSector Rank
PE 36.64
Fwd PE 14.59
P/S 0.44
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)0.11
EY2.73%
EPS(NY)0.28
Fwd EY6.85%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS9.09
BVpS8.03
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.73%
ROE -17.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.89%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.53%
Cap/Sales 3.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.78
Altman-Z 0.45
F-Score5
WACC9.83%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)237.5%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-39.33%
EPS Next 2Y45.76%
EPS Next 3Y53.71%
EPS Next 5Y33.97%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.12%
Revenue Next Year0.79%
Revenue Next 2Y4.51%
Revenue Next 3Y5.51%
Revenue Next 5Y5.25%
EBIT growth 1Y34.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.12%
EBIT Next 3Y58.99%
EBIT Next 5Y55.69%
FCF growth 1Y79.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.16%
OCF growth 3YN/A
OCF growth 5YN/A